AAII – UTEP AI News Digest home
UTEP · AAIIAI News Digest
Archived digest · Week of Jan 12 - Jan 18, 2026

Applied AI news,
scored for your field

Each week the Institute for Applied AI Innovation reviews AI publications and scores them for Research Relevance, Educational Value, Innovation/Novelty, Practical Impact, Interdisciplinary Potential and Ethical/Policy Implications. Then it writes summaries for each discipline at UTEP.

Read the top 10 →
Your Discipline 7 stories

The Week at a Glance

Biological & Biomedical Sciences · Jan 12 - Jan 18, 2026

Biological & Biomedical Sciences. Molecular/cellular biology, biochemistry, epidemiology, toxicology, and biomedical discovery. Prefers translational research and lab-tech updates.
Departments: Biological Sciences, Pharmaceutical Sciences
Biological & Biomedical Sciences

AI Innovations Propel Drug Development and Neuroscience

Recent advancements in artificial intelligence are significantly influencing the fields of drug development and neuroscience. Notable collaborations, such as the partnership between Eli Lilly and NVIDIA to establish an AI co-innovation lab, highlight the growing investment in AI-driven healthcare solutions. Additionally, OpenAI's investment in Merge Labs aims to revolutionize brain-computer interfaces, while Owkin's AI platform seeks to enhance pharmaceutical insights. These developments underscore a transformative shift towards integrating AI technologies in biological and biomedical research.

Download the PDF Digest
Key Findings
  • MIT's SQI focuses on interdisciplinary research to understand intelligence.
  • UCSD's new data compression technique enhances scalability in pangenomics.
  • Eli Lilly and NVIDIA's partnership includes a $1 billion investment in AI infrastructure.
Implications
  • Increased collaboration between tech and pharmaceutical companies may accelerate drug development timelines.
  • Advancements in brain-computer interfaces could lead to breakthroughs in neurotechnology and mental health treatments.
  • AI's role in biological research may redefine traditional methodologies and enhance discovery processes.

Key Metrics

Numbers reported in that week's stories
$252 millionInvestment in Merge Labs by OpenAI
$1 billionInvestment commitment from Eli Lilly and NVIDIA
$130 millionRaised in Chai Discovery's Series B funding round
Weekly summary for Biological & Biomedical Sciences

Biological & Biomedical Sciences

Top articles by AAII Impact Score (out of 30).

Browse the archive ›
No. 1 · Computer Science

At MIT, a continued commitment to understanding intelligence

Research Computer ScienceBiological SciencesElectrical & Computer EngineeringPsychologyPhilosophy
· 01/14/2026
26/30 AAII Impact Score

AI Summary: The MIT Siegel Family Quest for Intelligence (SQI) is a newly renamed research unit within the MIT Schwarzman College of Computing, aimed at understanding the principles of intelligence through interdisciplinary collaboration among researchers in various fields. The initiative focuses on both the biological basis of intelligence in humans and animals and the engineering of artificial systems that can replicate these capabilities to solve complex real-world problems. Supported by a significant endowment from the Siegel Family, SQI organizes its research around long-term missions that address foundational questions about intelligence, with the goal of advancing both scientific understanding and technological innovation in artificial intelligence.

Topics: Science & ResearchBiological IntelligenceInterdisciplinary CollaborationArtificial System Engineering
AI Rubric Scores
Research Relevance
5
Educational Value
4
Innovation/Novelty
5
Practical Impact
4
Interdisciplinary Potential
5
Ethical/Policy Implications
3
Read the full article ›
No. 2 · Biological Sciences 26/30

UCSD: Compressed Data Technique Enables Pangenomics at Scale

· 01/16/2026
Research Biological SciencesComputer ScienceElectrical & Computer Engineering

AI Summary: Engineers at the University of California have introduced a novel data structure and compression technique aimed at enhancing the scalability of pangenomics. Led by Professor Yatish Turakhia from UC San Diego, the research details a compressive pangenomics approach that allows for the management of significantly larger genetic datasets. The findings were published in *Nature Genetics* on January 16, 2026.

Topics: Healthcare AIPangenomics ScalabilityData Compression TechniquesGenetic Dataset Management
AI Rubric Scores +
Research Relevance
5
Educational Value
4
Innovation/Novelty
5
Practical Impact
4
Interdisciplinary Potential
5
Ethical/Policy Implications
3
Read Full Article ›
No. 3 · Electrical & Computer Engineering 24/30

OpenAI Invests in Sam Altman’s New Brain-Tech Startup Merge Labs

· 01/15/2026
Business Electrical & Computer EngineeringBiological SciencesPsychologyPublic Health Sciences

AI Summary: OpenAI has announced its investment in Merge Labs, a neurotechnology startup co-founded by CEO Sam Altman, aimed at developing non-invasive brain-computer interface technology using ultrasound to read and modulate brain activity. Merge Labs has secured $252 million in funding from various investors, including Bain Capital and Gabe Newell, and plans to create interfaces that integrate biology, devices, and AI without the need for implants. The collaboration with OpenAI will focus on leveraging AI to enhance the functionality of these interfaces, potentially improving their ability to interpret neural signals and adapt to individual users. Merge Labs is a spinoff of the nonprofit Forest Neurotech, which continues to explore applications related to mental health and brain injury.

Topics: AI HardwareNon-invasive Brain-Computer InterfacesNeural Signal InterpretationAI-Enhanced Neurotechnology
AI Rubric Scores +
Research Relevance
4
Educational Value
3
Innovation/Novelty
5
Practical Impact
4
Interdisciplinary Potential
5
Ethical/Policy Implications
3
Read Full Article ›
No. 4 · Pharmaceutical Sciences 24/30

Q&A: Owkin CEO on building an AI scientist and pharma’s short-term thinking

· 01/16/2026
Business Pharmaceutical SciencesBiological SciencesPolitical Science & Public Administration

AI Summary: Thomas Clozel, cofounder and CEO of Owkin, discussed the company's AI platform that emphasizes biological insights during an interview at the JPM Healthcare Conference. He criticized the pharmaceutical industry's tendency to prioritize short-term pipeline successes over long-term innovation. Clozel's comments highlight a broader concern regarding the sustainability and effectiveness of current practices in drug development.

Topics: Healthcare AIAI in Drug DevelopmentBiological Insights ExtractionLong-term Innovation Strategies
AI Rubric Scores +
Research Relevance
3
Educational Value
4
Innovation/Novelty
4
Practical Impact
5
Interdisciplinary Potential
4
Ethical/Policy Implications
4
Read Full Article ›
No. 5 · Pharmaceutical Sciences 23/30

JPM: NVIDIA and Eli Lilly announce co-innovation AI lab

· 01/15/2026
Business Pharmaceutical SciencesComputer SciencePublic Health Sciences

AI Summary: Eli Lilly and Co. and NVIDIA announced a partnership to establish an AI co-innovation lab in San Francisco during the JPM Healthcare Conference. The collaboration includes an investment of up to $1 billion over five years, aimed at enhancing infrastructure, workforce development, and computational resources. This initiative seeks to leverage AI technologies in the pharmaceutical sector.

Topics: Healthcare AIAI in PharmaceuticalsAI Infrastructure DevelopmentWorkforce Development in AI
AI Rubric Scores +
Research Relevance
3
Educational Value
4
Innovation/Novelty
4
Practical Impact
5
Interdisciplinary Potential
4
Ethical/Policy Implications
3
Read Full Article ›
No. 6 · Biological Sciences 23/30

From OpenAI’s offices to a deal with Eli Lilly — how Chai Discovery became one of the flashiest names in AI drug development

· 01/16/2026
Business Biological SciencesPharmaceutical SciencesComputer ScienceElectrical & Computer Engineering

AI Summary: Chai Discovery, an AI startup founded in 2024, has raised significant funding, including $130 million in its recent Series B round, achieving a valuation of $1.3 billion. The company has partnered with Eli Lilly to utilize its AI algorithm, Chai-2, for developing antibodies aimed at accelerating drug discovery. This collaboration coincides with Eli Lilly's announcement of a $1 billion partnership with Nvidia to establish an AI drug discovery lab in San Francisco. Despite skepticism from some industry veterans regarding the impact of AI on traditional drug development, proponents believe that early adopters of such technologies will gain a competitive advantage in bringing new medicines to clinical trials.

Topics: Healthcare AIAI Drug DiscoveryAntibody DevelopmentChai-2 Algorithm
AI Rubric Scores +
Research Relevance
3
Educational Value
4
Innovation/Novelty
4
Practical Impact
5
Interdisciplinary Potential
4
Ethical/Policy Implications
3
Read Full Article ›
No. 7 · Computer Science 22/30

Can A.I. Generate New Ideas?

· 01/15/2026
Research Computer ScienceBiological SciencesChemistry & BiochemistryMathematical Sciences

AI Summary: Recent advancements in AI systems, such as OpenAI's GPT-5, are significantly enhancing research capabilities in fields like mathematics, biology, and chemistry. However, there is an ongoing debate regarding the extent to which these systems can independently conduct research without human intervention. The discussion highlights the limitations and potential roles of AI in scientific inquiry, emphasizing the need for further exploration of AI's capabilities in these domains.

Topics: Generative AIAI in Scientific InquiryResearch AutomationAI-Assisted Discovery
AI Rubric Scores +
Research Relevance
4
Educational Value
3
Innovation/Novelty
3
Practical Impact
4
Interdisciplinary Potential
4
Ethical/Policy Implications
4
Read Full Article ›
Audio Summary

Generating...

Weekly Digest Summary

Error.

AI News Chatbot
...
$0.0000
AI

Hello! Ask me anything about this weeks digest.